Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Study ID
NCT02296203

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

CRICKET

Trial Summary

This is a multicentric, phase II single-arm study in which KRAS, NRAS and BRAF wild-type, irinotecan-resistant metastatic colorectal cancer patients progressing after an initial response to a first-line cetuximab-containing therapy, receive a rechallenge third-line treatment with cetuximab plus irinotecan.

More informations

Trial Starting Date

Oct 31,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit